1 / 2

Jakavi 5mg(Ruxolitinib)-Uses, Side Effects, Substitutes, Composition And More|Apple Pharmaceuticals

Jakavi 5mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production

RobbieRoyce
Download Presentation

Jakavi 5mg(Ruxolitinib)-Uses, Side Effects, Substitutes, Composition And More|Apple Pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. JAKVI 5MG DESCRIPTION Jakavi 5mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production. Jakavi 5mg is prescription drug provided under supervision of doctors or pharmacists INDICATION Jakavi 5mg is indicated for the treatment in patients with intermediate and high-risk myelofibrosis. MECHANISM Ruxolitinib is also knowns kinase inhibitor which is discriminating for the Janus analogue Kinases (JAK) 1 and 2. These kinases are required for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The communicate process involves signal transducers and transcription activators (STAT) that modulate gene expression. Patients having myelofibrosis consist of abnormal JAK1 and JAK2 activity,Therefore Ruxolitinibfunction to regulate this. DOSAGE Myelofibrosis: Kinase inhibitor uses for treatment of patients with intermediate or high-risk myelofibrosis, involving mainly myelofibrosis, post-polycythemiavera myelofibrosis and post-essential thrombocythemia myelofibrosis Starting recommended doses for myelofibrosis: If Platelet count >200 x10^9/L the dose given is 20 mg PO BID If Platelet count 100-200 x10^9/L the dose given is 15 mg PO BID If Platelet count 50 to <100 x10^9/L the dose given is 5 mg PO BID

  2. Titrate dose based on response; not to exceed 25 mg PO BID. Polycythemia Vera: The recommended dose is 10mg PO BID Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used. DRUG INTERACTION Concomitant use with fluconazole doses greater than 200mg daily may increase Ruxolitinib exposure leads to increase the risks of exposure related adverse reaction. Interaction of Jakavi 5mg with strong CYP3A4 inhibitors will increases Ruxolitinib exposure. Interaction of Jakavi 5mg with strong CYP3A4 inducers will decreases Ruxolitinib exposure. STORAGE Jakavi 5mg stored at 20° to 25° Protect away from light and moisture Dispense in its original container MISSED DOSE If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. Consult doctors regarding missed dose. Avoid taking double the dose.

More Related